To characterize the pharmacokinetics ( PK ) and pharmacodynamics ( PD ) of a new insulin glargine comprising @ units mL ( -@ ) ( Gla-@ ) , compared with insulin glargine @ units mL ( -@ ) ( Gla-@ ) at steady state in people with type @ diabetes .